Scott J. Diede

发表

Spontaneous regression of metastatic cancer: learning from neuroblastoma

Scott J. Diede, 2014, Nature Reviews Cancer.

Assessment of palindromes as platforms for DNA amplification in breast cancer.

S. Tapscott, Hisashi Tanaka, P. Porter, 2012, Genome research.

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

D. Schadendorf, V. Sondak, P. Ascierto, 2022, The Lancet.

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

J. Wolchok, A. Ribas, F. Hodi, 2021, European journal of cancer.

Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.

R. Fisher, A. Ribas, F. Hodi, 2016 .

Telomerase-Mediated Telomere Addition In Vivo Requires DNA Primase and DNA Polymerases α and δ

D. Gottschling, Scott J. Diede, 1999, Cell.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

James R. Anderson, J. Wolchok, H. Zarour, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

S. Haferkamp, R. Dummer, J. Kirkwood, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

A. Carneiro, G. Long, L. Ny, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

James R. Anderson, J. Kirkwood, A. Ribas, 2021, Annals of Oncology.

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

P. Ascierto, A. Ribas, M. Del Vecchio, 2021, European journal of cancer.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state.

S. Tapscott, Yi Cao, F. Dilworth, 2009, Genes & development.

Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors

Abraham P. Fong, Zizhen Yao, S. Tapscott, 2012, Molecular and Cellular Biology.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences

J. Olson, S. Tapscott, Hisashi Tanaka, 2009, Proceedings of the National Academy of Sciences.

Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review

Huilin Tang, Jiali Han, I. Shui, 2022, Cancers.

A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

J. Malvehy, R. Dummer, J. Kirkwood, 2016 .

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

Yanhong Gu, H. Pan, Y. Shu, 2022, Frontiers in Immunology.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Michael E. Lassman, J. Malvehy, R. Dummer, 2017, Cell.

Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases

Huilin Tang, Jiali Han, I. Shui, 2022, Frontiers in Oncology.

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.

P. Ascierto, A. Ribas, H. Schmidt, 2022, Journal of Clinical Oncology.

Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Jedd D. Wolchok, Antoni Ribas, Richard F. Kefford, 2016 .

A duplication at chromosome 11q12.2–11q12.3 is associated with spinocerebellar ataxia type 20

D. Hernandez, A. Singleton, K. Fischbeck, 2008, Human molecular genetics.

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

A. Carneiro, G. Long, L. Ny, 2020 .

EEL-1, a Hect E3 ubiquitin ligase, controls asymmetry and persistence of the SKN-1 transcription factor in the early C. elegans embryo

Scott J. Diede, E. L. Ferguson, Jennifer R. Tenlen, 2007, Development.

Preliminary results of ENCORE 601, a phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC).

George A. Dominguez, P. Jänne, S. Ramalingam, 2016 .

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

A. Carneiro, A. Arance, G. Long, 2021, Journal of Clinical Oncology.